Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9P2I0
UPID:
CPSF2_HUMAN
Alternative names:
Cleavage and polyadenylation specificity factor 100 kDa subunit
Alternative UPACC:
Q9P2I0; B3KME1; Q6NSJ1; Q9H3W7
Background:
The Cleavage and polyadenylation specificity factor subunit 2, also known as the 100 kDa subunit, is integral to pre-mRNA 3'-end formation. It recognizes the AAUAAA signal sequence, facilitating cleavage and poly(A) addition by interacting with poly(A) polymerase and other factors. This protein also plays a role in histone 3' end pre-mRNA processing.
Therapeutic significance:
Understanding the role of Cleavage and polyadenylation specificity factor subunit 2 could open doors to potential therapeutic strategies.